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An HFE Intronic Variant Promotes Misdiagnosis of
Hereditary Hemochromatosis
To the Editor:
Hereditary hemochromatosis (HH; MIM 235200), an
autosomal recessive disorder of iron metabolism, can
result in numerous clinical complications and is esti-
mated to affect ∼1/300 individuals of northern European
origin (Merryweather-Clarke et al. 1997). Two muta-
tions—C282Y and H63D—that contribute to HH have
been identified (Feder et al. 1996), and screening for the
C282Y mutation, in particular, is routinely done to iden-
tify carriers and affected individuals. Biochemical mark-
ers indicate a relatively clear distinction between these
two groups, with minimal clinical consequences for het-
erozygotes (Bulaj et al. 1996). We initiated screening for
the C282Y mutation, using the primer sequences pro-
vided by Feder et al. (1996) and subsequent restriction
digestion of PCR products (Jazwinska et al. 1996). Re-
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Figure 1 PCR amplification and SnaBI digestion of DNA (Ja-
zwinska et al. 1996) from individuals referred for HH testing. Lane
1, C282Y carrier. Lane 2, Normal homozygote. Lane 3, C282Y ho-
mozygote. Lane 4, Individual with an anomalous pattern with trace
amounts of undigested PCR product. All 25-ml PCR reactions were
performed in parallel, with use of 150 ng DNA template and 1.25 U
PLATINUMTaq (GIBCO-BRL), in 20 mM Tris-HCl (pH 8.4), 50
mM KCl, and 1.5 mM MgCl2. PCR conditions were as follows: 94C
for 2 min; then 30 cycles at 94C for 30 s, 65C for 30 s, and 72C
for 30 s; and a final extension at 72C for 10 min, by means of a
GeneAmp PCR System 9600 (Perkin-Elmer). PCR products were di-
gested with SnaBI at 37C for 3 h and were resolved by use of 1.5%
agarose gel.
Figure 2 DNA sequence of HFE exon 4, with flanking introns.
The relative locations of the C282Y mutation (GrA) in exon 4 and
the 5569 GrA (89248 GrA) polymorphism in intron 4 are shown.
Sequences and locations are highlighted for Feder et al. (1996) forward
and reverse primers and for the two alternative flanking primers (HCS:
F and HCS:R) that were used to amplify this region. Conditions for
PCR with HCS:F and HCS:R followed those outlined for the Feder et
al. primer set (fig. 1), with an annealing temperature of 55C. The
486-bp HCS PCR product was cleaved into 320- and 166-bp fragments
by SnaBI in the presence of the C282Y mutation. The intronic poly-
morphism was confirmed, by sequencing and by MseI digestion of
HCS PCR products, in all samples that showed an anomalous SnaBI
digestion pattern by use of Feder et al. (1996) PCR products.
cently, we have identified anomalous results in some in-
dividuals while screening for the presence of the C282Y
mutation. We initially identified eight individuals, seven
of whom were unrelated, who appeared to be C282Y
homozygotes with trace amounts of undigested DNA
(fig. 1). It was assumed that these individuals were ho-
mozygotes with some form of sample contamination.
Clinical histories of these individuals did not include
previous blood transfusion or tissue transplantation. In-
creased amounts of restriction enzyme and incubation
time, as well as resampling of these individuals, did not
resolve the anomalous results. An increase in the strin-
gency of the PCR conditions, achieved either by increas-
ing the annealing temperature or by decreasing the
amount of genomic template, reduced the amount of
amplified normal product to generate a C282Y homo-
zygote pattern (results not shown). Biochemical data on
serum iron levels, serum ferritin levels, and transferrin
saturation were available for two of these individuals—a
35-year-old man and a 71-year-old woman—and values
were below the affected range. In one particular family,
two sibs showed this pattern, yet, when their parents
were tested, only the mother was found to be a C282Y
carrier. In this instance, a combination of two indepen-
dent incidents of nonpaternity and sample contamina-
tion would be required to explain the results.
We reanalyzed these cases, using two different ap-
proaches: (1) the Baty et al. (1998) amplification re-
fractory mutation system (ARMS), which includes an
alternative reverse primer with the Feder et al. (1996)
forward primer, and (2) a modification of the previous
protocol (Jazwinska et al. 1996) to incorporate two al-
ternative primers that flank the Feder et al. primer sites
(fig. 2). With both techniques, we found that all eight
samples gave a clear carrier pattern for C282Y (results
not shown). In all cases, sequencing across the Feder et
al. primer sites revealed a GrA substitution at nucleotide
position 5569 (GenBank accession number Z92910) on
the non-C282Y allele. This sequence variant is located
in intron 4, 5 bases from the 3′ terminus of the reverse-
primer site identified by Feder et al., and is not predicted
to disrupt normal hemochromatosis gene (HFE) splic-
ing (fig. 2). In all eight samples, this mutation was seen
on a non-C282Y, non-H63D chromosome. PCR using
this reverse primer can result in dramatically reduced
amplification of the polymorphic allele, such that a
C282Y carrier can appear to be a C282Y homozygote.
The relative intensity of the non-C282Y PCR product
is inversely proportional to the stringency of the PCR
conditions. Sequencing of both alleles in the eight in-
dividuals in the present study allowed clear assignment
of carrier, rather than affected, status.
The 5569 GrA substitution introduces an MseI re-
striction site. We used this enzyme, in conjunction with
the Feder et al. (1996) forward primer and the HCS:
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R primer, to screen 48 individuals (45 of whom were
unrelated) whom we had previously identified as
C282Y homozygotes. In this group, we identified one
additional unrelated individual with the C282Y mu-
tation and the 5569 GrA polymorphism. Closer ex-
amination of the assay on the basis of which the pre-
vious diagnosis was made in this individual revealed
an extremely faint normal band that had been inter-
preted to result from partial digestion. In total, there-
fore, the polymorphism has been found in 8 of 202
unrelated individuals who were referred for HH testing.
An estimate of the allele frequency can be made on the
basis of the C282Y carrier frequency. We found these
8 polymorphism carriers among a total of 43 unrelated
C282Y (non-H63D) carriers. Our estimated popula-
tion frequency of this allele is, therefore, 8/43 (=.186).
Consequently, in our population, this polymorphism
had the potential to result in ∼19% of C282Y heter-
ozygotes being misidentified as homozygotes.
We identified the 8 polymorphism carriers, in addi-
tion to 44 unrelated C282Y homozygotes, from our
total sample of 202 unrelated individuals referred for
testing. If the assumption of homozygosity, along with
access to parental genotypes, had been made in all in-
dividuals with the polymorphism, as well as in those
with the homozygosity, this would have led to an es-
timate of ∼8/52 (=.154) for nonparentage, of which
half of these cases, or 8%, would have been assumed
to result from nonpaternity. The frequency of this poly-
morphism is high enough to warrant concern that the
interpretation of homozygosity in these cases will result
in an overestimate of the C282Y-allele frequency, a mis-
diagnosis of this condition, and an incorrect assump-
tion of nonpaternity in some families. In our hands,
the polymorphism promoted misinterpretation of a re-
striction-digestion–based assay, but any form of anal-
ysis (including allele-specific oligonucleotide hybridi-
zation, ARMS, or direct sequencing) that incorporates
the Feder et al. (1996) reverse primer is equally prone
to misdiagnosis. It is recommended that all laboratories
using the Feder et al. reverse primer to test for the
C282Y mutation confirm C282Y-homozygote results
by using a flanking primer set and MseI digestion.
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No Mutations in the Coding Region of the PRKCG
Gene in Three Families with Retinitis Pigmentosa
Linked to the RP11 Locus on Chromosome 19q
To the Editor:
Retinitis pigmentosa (RP) and allied degenerations of the
retina are genetically heterogeneous, with well over 50
loci implicated so far through gene identifications or
linkage-based chromosomal assignments. Among these
genes, the dominantly inherited RP11 locus (MIM
600138) on chromosome 19q is noteworthy because
some carriers develop RP that is symptomatic at age !20
years, whereas others are asymptomatic and show no
funduscopic or electroretinographic signs of disease even
at age 170 years (Berson et al. 1969; Berson and Si-
monoff 1979; Evans et al. 1995; Nakazawa et al. 1996;
McGee et al. 1997). On the basis of its chromosomal
